SFROWASA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7645801 | MYLAN SPECIALITY LP | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
Jul, 2027
(3 years from now) | |
Sfrowasa is owned by Mylan Speciality Lp.
Sfrowasa contains Mesalamine.
Sfrowasa has a total of 1 drug patent out of which 0 drug patents have expired.
Sfrowasa was authorised for market use on 24 December, 1987.
Sfrowasa is available in enema;rectal dosage forms.
The generics of Sfrowasa are possible to be released after 24 July, 2027.
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 24 December, 1987
Treatment: NA
Dosage: ENEMA;RECTAL
More Information on Dosage
SFROWASA family patents
